Life sciences stories
EY-Parthenon says dealmaking is shifting towards AI and technology as 87% of UK chief executives expect their M&A appetite to rise.
The brownfield deal could ease capacity pressure in London, where cloud providers and AI users are competing for scarce land and power.
Yet only 15 per cent have deployed OT-specific visibility tools, even as cyber incidents have already disrupted critical systems for most respondents.
The rankings bolster Altimetrik's push to win larger contracts from drugmakers as life sciences firms seek AI that improves regulated operations.
Search now blends text, images and files as Google rolls out a single AI experience and background agents to over 1 billion users.
Researchers will gain tools to cut literature review and modelling time as Google opens access to experimental Gemini for Science features gradually.
The UK industrial AI company is stepping up its North American push as it seeks to turn existing US customers into broader revenue growth.
Search users will get background AI agents and custom layouts as Google broadens Gemini across its apps, YouTube and Workspace.
The move will put AVEVA's industrial data platform on AWS, giving customers more cloud choice and access to AI tools across operations.
Poor data quality has been slowing enterprise AI roll-outs, prompting Denodo to link live governed data to AWS agentic tools across multiple services.
The purchase will add more than 1,000 Azure engineers and AI specialists as NTT Data targets larger enterprise roll-outs on Microsoft cloud tools.
The consultancy is betting on growing demand for better use of planning software as companies seek tighter inventory control and more reliable forecasting.
QuEra survey finds quantum buyers and backers are demanding stronger proof of value, even as 46% of organisations expect budgets to stay flat.
AI in life sciences is boosting workflows rather than replacing scientists, as firms navigate regulation, data risks and uneven adoption across markets.
Life sciences firms could avoid costly FDA review delays as the software flags conflicting claims across filings before submissions are sent.
The new tools give life sciences finance teams clearer trial spending forecasts and scenario planning after a USD $24 million Series A round.
The platform is aimed at regulated industries and sensitive data users, with on-premise and air-gapped deployment to keep control in-house.
Drug makers face new filing deadlines in China, as eligible trial data can now be shielded for up to six years from copycat use.
The pact will widen use of AI in Singapore's public services, schools and labs, while adding new tests on safety, governance and inclusion.
Healthtech startups are finding it harder to scale as weaker exits and tighter liquidity help drive Canadian VC investment down to CAD $1 billion in 2025.